The global Targeted Protein Degradation (TPD) Therapy Drugs market size is predicted to grow from US$ 19801 million in 2025 to US$ 39443 million in 2032; it is expected to grow at a CAGR of 10.9% from 2026 to 2032.

In 2025, global Targeted protein degradation (TPD) Therapy Drugs reached approximately 1338 K Units, with an average global market price of around 121.33 USD per Unit.

Targeted Protein Degradation (TPD) therapy drugs are a class of innovative medicines that treat disease by selectively eliminating specific proteins inside cells, rather than merely inhibiting their activity. These therapies work by harnessing the cell?s natural protein disposal systems, most commonly the ubiquitin?proteasome pathway or, in some cases, lysosomal degradation pathways, to remove disease-causing or disease-driving proteins.

Targeted protein degradation (TPD) Therapy Drugs are an emerging class of small-molecule medicines designed to treat disease by selectively removing, rather than merely inhibiting, specific proteins through the cell?s own ubiquitin?proteasome degradation system. This ?event-driven? mechanism addresses several persistent pain points in drug development: it can overcome situations where conventional inhibitors lose effectiveness due to resistance mutations, it can achieve deeper and more sustained pathway control by eliminating the target protein altogether, and it opens new possibilities for proteins that are difficult to modulate with classic active-site binding strategies. Industry momentum is being fueled by rapid advances in target biology and structural design, growing confidence in the translational value of targeted protein degradation, and strong demand in areas such as oncology and immune-mediated diseases where durable responses and differentiation matter most. Looking ahead, market potential is supported by an expanding pipeline of degrader programs, improving chemistry and drug-like properties that enable more practical dosing and broader tissue reach, and the likelihood that successful Targeted protein degradation (TPD) Therapy Drugs will complement?rather than simply replace?existing targeted therapies, creating a meaningful new layer of precision medicine built around controlling protein levels instead of just protein activity.

The upstream raw materials for Targeted Protein Degradation (TPD) Therapy Drugs mainly include target protein (POI) ligands, E3 ligase ligands, excipients, etc. Typical suppliers include Bio-Techne, Merck, Sigma-Aldrich, Enamine, etc. The downstream applications are mainly in the treatment of cancer, immune diseases, etc.

The production capacity of Targeted protein degradation (TPD) Therapy Drugs varies significantly depending on the technology route, production stage, and commercialization progress. The gross profit margin of Targeted protein degradation (TPD) Therapy Drugs is usually between 70-80%.

United States market for Targeted Protein Degradation (TPD) Therapy Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Targeted Protein Degradation (TPD) Therapy Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Targeted Protein Degradation (TPD) Therapy Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Targeted Protein Degradation (TPD) Therapy Drugs players cover BMS, Arvinas, Kymera, Nurix, C4 Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

Infinity Market Research newest research report, the ?Targeted Protein Degradation (TPD) Therapy Drugs Industry Forecast? looks at past sales and reviews total world Targeted Protein Degradation (TPD) Therapy Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Targeted Protein Degradation (TPD) Therapy Drugs sales for 2026 through 2032. With Targeted Protein Degradation (TPD) Therapy Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Protein Degradation (TPD) Therapy Drugs industry.

This Insight Report provides a comprehensive analysis of the global Targeted Protein Degradation (TPD) Therapy Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Targeted Protein Degradation (TPD) Therapy Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Targeted Protein Degradation (TPD) Therapy Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Protein Degradation (TPD) Therapy Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Protein Degradation (TPD) Therapy Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Protein Degradation (TPD) Therapy Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    PROTAC
    Molecular Glues
    Others
    Segmentation by Target Protein:
    Degradation of Transcription Factors Type
    Degradation of Scaffold Proteins Type
    Others
    Segmentation by Administration Route:
    Oral Drugs
    Injectable Drugs
    Others

Segmentation by Application:

    Cancer
    Immune Diseases
    Others

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration.

    BMS
    Arvinas
    Kymera
    Nurix
    C4 Therapeutics
    Cullgen
    Kintor Pharma
    Prelude Therapeutics
    AbbVie
    Accutar
    AnHorn Medicines
    Astellas
    Auron Therapeutics
    Axter Therapeutics
    Biotheryx
    Dialectic Therapeutics
    Hinova
    Hinova Pharmaceuticals
    Haisco
    Leadingtac
    Mitsubishi Tanabe Pharma America
    NiKang Therapeutics
    Ubix Therapeutics
    Foghorn Therapeutics
    Beigene, Ltd.
    Jiangsu Hengrui Medicine
    Qilu Pharmaceutical
    Simcere Pharma
    Chia Tai Tianqing Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Targeted Protein Degradation (TPD) Therapy Drugs market?
What factors are driving Targeted Protein Degradation (TPD) Therapy Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Targeted Protein Degradation (TPD) Therapy Drugs market opportunities vary by end market size?
How does Targeted Protein Degradation (TPD) Therapy Drugs break out by Type, by Application?